Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Kabra Drugs Ltd (NSE: KABRADG), ISIN INE323K01017 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
KABRADG last traded at ₹18.01 (+3.57%), with a 52-week range of ₹15.25 to ₹35.52 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 0.00%, FIIs 0.00%, DIIs 0.00%, mutual funds 0.00%.
EquiSense Score (ECS): 48/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.